Factors affecting the specificity and mechanism of action of antisense oligonucleotide

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 4, 1999, Pages 371-375

  Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748203758     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. AGRAWAL, S. (1996). Antisense oligonucleotides: Towards clinical trials. Trends Biotechnol 14, 376-387.
2. AGRAWAL, S. (1999). Importance of nucleotide sequences and chemical modifications of antisense oligonucleotides. Biochem. Biophys. Acta In press.
3. AGRAWAL, S., IADOROLA, P.L., TEMSAMANI, J., ZHAO, Q., and SHAW, D. (1996). Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides. Bioorg. Med. Chem. Lett. 6,2219-2224.
4. AGRAWAL, S., and IYER, R.P. (1995). Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6,12-19.
5. AGRAWAL, S., JIANG, Z., ZHAO, Q., SHAW, D., CAI, Q., ROSKEY, A., CHANNAVAJJALA, L., SAXINGER, C., and ZHANG, R. (1997a). Mixed-backbone oligonucleotides as secondgeneration antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94,2620-2625.
6. AGRAWAL, S., and KANDIMALLA, E. (1999). Medicinal chemistry of antisense oligonucleotides. In: Antisense Technology in the CNS. R. Leslie, ed. (Oxford University Press, Oxford, U.K.).
7. AGRAWAL, S., MAYRAND, S.M., ZAMECNIK, P.C., and PEDERSON, T. (1990). Site specific excision from RNA by RNase H and mixed phosphate backbone oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 87,1401-1405.
8. AGRAWAL, S., TAN, W., CAI, Q., XIE, X., and ZHANG, R. (1997b). In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 7, 245-249.
9. AGRAWAL, S., and TEMSAMANI, J. (1996). Oligonucleotides as antiviral agents. In: Antisense Oligonucleotides: From Technology to Therapy. K.H. Schlingensiepen, ed. (Blackwell, Berlin), pp. 225-250.
10. AGRAWAL S, TEMSAMANI J, GALBRAITH W., and TANG J.Y. (1995a). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28,7-16.
11. AGRAWAL, S., and ZHANG, R. (1998). Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administration in experimental animals. In: Antisense Research and Application Handbook of Experimental Pharmacology. S.T. Crooke, ed. (Springer, Berlin) pp. 525-543.
12. AGRAWAL, S., ZHANG, X., CAI Q., KANDIMALLA, E.R., MANNING, A., JIANG, Z., MARCEL, T., and ZHANG, R. (1998). Effect of aspirin on protein binding and tissue disposition of oligonucleotides phosphorothioate in rats. J. Drug Targ. S, 303-312.
13. AGRAWAL, S., ZHANG, X., ZHAO, H., LU, Z., YAN, J., CAI, H., DIASIO, R.B., HABUS, I., JIANG, Z., IYER, R.P., YU, D., and ZHANG, R. (1995b). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biopharmacol. 50, 571-576.
14. AGRAWAL, S., and ZHAO, Q. (1998). Antisense therapeutics. Curr. Opin. Chem. Biol. 2, 519-528.
15. BENNETT, C.F. (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol, 55,9-19.
16. BERGAN, R., CONNELL, Y., FAHMY, B., KYLE, E. and NECKERS, L. (1994). Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res. 22,2150-2154.
17. BRANCH, A.D. (1998). A good antisense molecule is hard to find. Trends Pharmacol. Sci. 23, 39-50.
18. BRAND A, R.F., MOORE, A.L., MATHEWS, L., McCORMACK, J.J., and ZON, G. (1993). Immune stimulation by an antisense oligo complementary to the rev gene of HIV-1. Biochem. Pharmacol. 45, 2037-2043.
19. BURGESS, T.L., FISHER, E.F., ROSS, S.L., BREADY, J.V., QIAN, Y., BAYEWITCH, L.A., COHEN, A.M., HERRA, C.J., HUSS, F., KRAMER, T.B., LOTT, F.D., MARTIN, F.H., PIERCE, G.F., SIMONEC, L., and FARRELL, C.L. (1995). The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA 92,4051-4055.
20. CASTIER, Y., CHEMLA, E., NRAT, J., HEUDES, D., VASSEUR, M.A., RAJNOCH, C., BRUNEVAL, P., CARPENTER, A., and FABIANI, J.N. (1998). The activity of c-myb antisense oligonucleotide to prevent intimai hyperplasia is nonspecific. J. Cardiovasc. Surg. 39,1-7.
21. CHEN, H. (1998). Phase I evaluation of GEM 231, a second generation oligonucleotide targeted at type 1 protein kinase A (PKA-1) in patients with refractory solid tumors. Antisense 98, organized by Nature Biotechnology (abstract).
22. CHEN, L., AGRAWAL, S., ZHOU, W., ZHANG, R., and CHEN, J. (1998). Synergistic activation of p53 by inhibition of mdml expression and DNA damage. Proc. Natl. Acad. Sci. USA 95,195-200.
23. DEAN, N.M., and McKAY, R. (1994). Inhibition of protein kinase C α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides Proc. Natl. Acad. Sci. USA 91, 11762-11766.
24. DUNFORD, P.J., MULQUEEN, M.J., and AGRAWAL, S. (1997). Nonspecific oligonucleotides containing CpG motifs protect against lethal viral infections in mice, Antisense 97: Targeting the Molecular Basis of Disease (Cambridge, MA) (abstract).
25. GALBRAITH, W.M., HOBSON, W.C., GICLAS, P.C., SCHECHTER, P.J., and AGRAWAL, S. (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4,201-206.
26. CAO, W.Y., HAN, F.S., STORM, C., EGAN, W., and CHENG, Y.C. (1992). Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology. Mol Pharmacol. 41,223-229.
27. GEWIRTZ, A.M., SOKOL, D.L., and RATAJCZAK, M.Z. (1998). Nucleic acid therapeutics: State of the art and future prospects. Blood 92,712-736.
28. GILES, R.V., SPILLER, D.G., and TIDD, D.M. (1995). Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5,23-31.
29. GUVAKOVA, M.A., YAKUBOV, L.A., VLODAVSKY, I., TONKINSON, J.L., and STEIN, C.A. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270,2620-2627.
30. HACKER, H., MISCHAK, H., MffiTHKE, T., LIPTAY, S., SCHMID, R., SPARWASSER, T., HEEG, K., LIPFORD, G.B., and WAGNER, H. (1998). CpG-DNA-specific activation of antigen-presenting cells requires stress kinase and is preceded by non-specific endocytosis and endsomal maturation. EMBO J. 17, 6230-6240.
31. HENRY, S.P., LEEDS, J., GICLASS, P.S.C., GILLETT, N.A., FRIBBLE, J.P., KORNBRUST, D.J., and LEVIN, A.A. (1997). The toxicity of ISIS 3521, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120,145-155.
32. HO, S.P., BAO, Y., LESHER, T., CONKLFN, D., and SHARP, D. (1999). Regulation of the antgiotesin type-1 receptor by antisense oligonucleotides occurs through an RNase H-type mechanism. Brain Res. Mol. Brain Res. 65,23-33.
33. KANDIMALLA, E.R., SHAW, D.R., and AGRAWAL, S. (1998). Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotide on human complement and coagulation. Bioorg. Med. Chem. Lett. 8,2102-2108.
34. KTTA, K., SAITO, S., MORIOKA, C.Y., and WATANABE, A. (1999). Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int. J. Cancer 80, 553-558.
35. KLINMAN, D.M., BEAUCAGE, S.L., CONOVER, J., and KREIG, A.M. (1996). CpG motifs expressed by bacterial DNA rapidly induced lymphocytes to secret IL-6, IL-12 and IFN-gamma. Proc. Natl. Acad. Sci. USA 93,2879-2883.
36. KRIEG, A.M., LOVE-HOMAN, L., YI, A.K., and HARTY, J.T. (1998). CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161, 2428-2434.
37. KRIEG, A.M., MATSON, S., CHENG, K., FISHER, E., KORETZKY, G.A., and KOLAND, J.G. (1997). Identification of an oligodeoxynucleotides sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. Antisense Nucleic Acid Drug Dev. 7, 115-123.
38. KRIEG, A.M., MATSON, S., WALDSCHM1DT, T.J., BISHOP, G.A., TEASDALE, R., KORETZKY G.A., and KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374,546-549.
39. MASOOD, R., CAI, J., ZHENG, T., SMITH, D.L., NAIDU, Y., and GILL, P.S. (1997). Vascular endothetial growth factor/vascular permeability factor is an automne growth factor for AIDS-Kaposi sarcoma. Proc. Natl. Acad. Sci. USA 94, 979-984.
40. METELEV, V., LISZIEWICZ, J., and AGRAWAL, S. (1994). Study of antisense oligonucleotide phosphorothioates containing segments of 2'-O-methyloligoribonucleotides, Bioorg. Med. Chem. Lett. 4, 2929-2934.
41. MOLDOVEANU, Z., LOVE-HOMAN, L., HUANG, W.Q., and KREIG, A.M. (1998). CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216-1224.
42. MONIA, B.P., JOHNSTON, J., GEIGER, T., MULLER, M., and FABBRO, D. (1995). Antitumor activity of a phosphorothioate oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668-675.
43. OSEN-SAND, A., CATSICAS, M., STAPLE, J.K., JONES, K.A., AYALA, G., KNOWLES, J., GRENNINGLOH, G., and CATSICAS, S. (1993). Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. Nature 364, 445148.
44. PARK, Y.G., NESTEROVA, M., AGRAWAL, S., and CHO-CHUNG, Y.S. (1999). Dual blockade of cyclic amp response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. Gene specific inhibition of tumor growth. J. Biol. Chem. 15, 1573-1580.
45. PISETSKY, D.S. (1996). Immune activation by bacterial DNA: A new genetic code. Immunity 5, 303-310.
46. SHAW, D.R., RUSTAGI, P.K., KANDIMALLA, E.R., MANNING, A.M., JIANG, Z., and AGRAWAL, S. (1997). Effects of synthetic oligonucleotides on human complement and coagulation. Biochem. Pharmacol. 53, 1123-1132.
47. TANG, J.Y., ROSKEY, A., and AGRAWAL, S. (1993). Method for sequencing synthetic oligodeoxynucleotide phosphorothioates. Anal. Biochem. 212, 134-137.
48. TOMITA, N., HORIUCHI, M., TOMITA, S., GIBBONS, G.H., KIM, J.Y., BARAN, D., and DZAU, V.J. (1998). An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am. J. Physiol. 275, F278-284.
49. VEAL, G.J., AGRAWAL, S., and BYRN, R.A. (1998). Sequence specific RNaseH cleavage of Gag mRNA from HIV-1 infected cells by an antisense oligonucleotide. Nucleic Acids Res. 26, 5670-5675.
50. WANG, W., CHEN, HJ., SUN, J., BENIMETSKAYA, L., SCHWARTZ, A., CANNON, P., STEIN, C.A., and RABBANI, L.E. (1998). Comparison of guanosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation. Antisense Nucleic Acid Drug Dev. 8,227-236.
51. WOOLDRIGE, J.E., BALLAS, Z., KREIG, A.M., and WEINER, G.J. (1997). Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89,2294-2998.
52. YI, A.K., and KRIEG, A.M. (1998). Rapid induction of mitogen-activated protein kinase by immune stimulatory CpG DNA. J. Immunol. 161,4493-M97.
53. YOKOZAKI, H., BUDILLON, A., TORTORA, G., MEISSNER, S., BEAUCAGE, S.L., MIKI, K., and CHO-CHUNG, Y.S. (1993). An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. S3, 868-872.
54. ZAMECNIK, P.C., and STEPHENSON, M.L. (1978). Inhibition of Rous sarcoma virus replication and transformation by a specific oligonucleotide. Proc. Natl. Acad. Sci. USA 7, 5280-5284.
55. ZHANG, R., LU, Z., LIU, T., ZHAO, H., ZHANG, X., DIASIO, R., HABUS, I., JIANG, Z., IYER, R.P., YU, D., and AGRAWAL, S. (1995). In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50, 545-556.
56. ZHAO, Q., TEMSAMANI, J., IADAROLA, P.L., JIANG, Z.W., and AGRAWAL, S. (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 51, 173-182.
57. ZHAO, Q., TEMSAMANI, J., ZHOU, R., and AGRAWAL, S. (1997). Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 79,495-502.
58. ZHOU, W., and AGRAWAL, S. (1998). Mixed-backbone oligonucleotides as second generation antisense agents with reduced phosphorothioate related side effects. Bioorg. Med. Chem. Lett. 8, 3269-3274.